Clareo Health | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Study study was terminated before the Phase 2 portion of the study began.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body weight \>= 35 kg.
Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease.
Measurable disease per Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1).
Prior history of or clinically stable concurrent malignancy are eligible for enrollment provided the malignancy is clinically insignificant, no treatment is required, and the participant is clinically stable.
You may not be if
Participants with locally advanced disease.
Participants with neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.
Prior radiotherapy, surgery, or systemic anti-cancer therapy for the treatment of metastatic pancreatic adenocarcinoma.
Prior radiotherapy, surgery, or systemic anti-cancer therapy in the adjuvant setting, or earlier, within the last 4 months.
Prior radiotherapy to any measurable metastatic lesion at any time.
Clinically significant third-space fluid accumulation (e.g., ascites or pleural effusion).
Known metastases to the central nervous system (CNS).
